| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
49,370,000 |
| Market
Cap: |
16.91(M) |
| Last
Volume: |
50,736 |
Avg
Vol: |
50,594 |
| 52
Week Range: |
$0.28 - $0.64 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. Co.'s two clinical-stage product candidates are zilovertamab and ONCT-216. Co. is developing ONCT-216, an investigational small molecule that inhibits the ETS, or E26 Transformation Specific, family of oncoproteins, which have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. In addition, Co. is developing ONCT-808, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
10,980 |
10,980 |
38,980 |
268,980 |
| Total Buy Value |
$95,117 |
$95,117 |
$104,941 |
$172,282 |
| Total People Bought |
2 |
2 |
3 |
7 |
| Total Buy Transactions |
4 |
4 |
6 |
14 |
| Total Shares Sold |
980 |
980 |
980 |
980 |
| Total Sell Value |
$8,859 |
$8,859 |
$8,859 |
$8,859 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
1 |
| End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wills Robert James |
Director |
– • – |
2024-04-08 |
4 |
B |
$8.96 |
$27,655 |
D/D |
3,086 |
10,000 |
2.39 |
- |
|
| Wills Robert James |
Director |
– • – |
2024-03-28 |
4 |
B |
$8.48 |
$58,602 |
D/D |
6,914 |
6,914 |
2.39 |
- |
|
| Hale David F |
Director |
– • – |
2024-02-23 |
4 |
B |
$9.04 |
$2,405 |
I/I |
266 |
29,673 |
2.02 |
- |
|
| Hale David F |
Director |
– • – |
2024-02-23 |
4 |
B |
$9.04 |
$6,455 |
D/D |
714 |
714 |
2.39 |
- |
|
| Wills Robert James |
Director |
– • – |
2024-02-23 |
4 |
S |
$9.04 |
$8,859 |
D/D |
(980) |
0 |
|
- |
|
| Breitmeyer James B |
Chief Executive Officer |
• • – |
2024-01-03 |
4 |
D |
$0.50 |
$2,225 |
I/I |
(4,485) |
15,426 |
|
- |
|
| Breitmeyer James B |
Chief Executive Officer |
• • – |
2024-01-03 |
4 |
D |
$0.50 |
$25,279 |
D/D |
(50,955) |
443,034 |
|
- |
|
| Vincent Richard G |
Chief Financial Officer |
• – – |
2024-01-03 |
4 |
D |
$0.50 |
$4,399 |
D/D |
(8,868) |
140,922 |
|
- |
|
| Krishnan Rajesh |
Chief Technical Officer |
• – – |
2024-01-03 |
4 |
D |
$0.50 |
$5,873 |
D/D |
(11,838) |
44,019 |
|
- |
|
| Yazji Salim |
Chief Medical Officer |
• – – |
2024-01-03 |
4 |
D |
$0.50 |
$9,794 |
D/D |
(19,742) |
128,635 |
|
- |
|
| Leavitt Chase C. |
General Counsel/Secretary |
• – – |
2024-01-03 |
4 |
D |
$0.50 |
$5,873 |
D/D |
(11,838) |
84,758 |
|
- |
|
| Yazji Salim |
Chief Medical Officer |
• – – |
2023-07-03 |
4 |
D |
$0.36 |
$5,868 |
D/D |
(16,299) |
148,377 |
|
- |
|
| Krishnan Rajesh |
Chief Technology Officer |
• – – |
2023-07-03 |
4 |
D |
$0.36 |
$3,923 |
D/D |
(10,897) |
55,857 |
|
- |
|
| Breitmeyer James B |
Chief Executive Officer |
• • – |
2023-07-03 |
4 |
D |
$0.36 |
$1,443 |
I/I |
(4,007) |
19,911 |
|
- |
|
| Breitmeyer James B |
Chief Executive Officer |
• • – |
2023-07-03 |
4 |
D |
$0.36 |
$17,277 |
D/D |
(47,992) |
493,989 |
|
- |
|
| Leavitt Chase C. |
General Counsel/Secretary |
• – – |
2023-07-03 |
4 |
D |
$0.36 |
$3,710 |
D/D |
(10,305) |
96,596 |
|
- |
|
| Vincent Richard G |
Chief Financial Officer |
• – – |
2023-07-03 |
4 |
D |
$0.36 |
$2,545 |
D/D |
(7,069) |
149,790 |
|
- |
|
| Kaufmann Gunnar F. |
Chief Scientific Officer |
• – – |
2023-06-14 |
4 |
B |
$0.36 |
$1,079 |
D/D |
3,000 |
94,726 |
2.66 |
-11% |
|
| Kaufmann Gunnar F. |
Chief Scientific Officer |
• – – |
2023-06-12 |
4 |
B |
$0.35 |
$8,745 |
D/D |
25,000 |
91,726 |
2.74 |
-7% |
|
| Breitmeyer James B |
Chief Executive Officer |
• • – |
2023-04-14 |
4 |
B |
$0.29 |
$14,930 |
I/I |
50,000 |
196,544 |
2.58 |
11% |
|
| Yazji Salim |
Chief Medical Officer |
• – – |
2023-04-14 |
4 |
B |
$0.30 |
$1,500 |
D/D |
5,000 |
164,676 |
2.66 |
11% |
|
| Breitmeyer James B |
Chief Executive Officer |
• • – |
2023-04-13 |
4 |
B |
$0.29 |
$29,000 |
I/I |
100,000 |
146,544 |
2.66 |
9% |
|
| Leavitt Chase C. |
General Counsel/Secretary |
• – – |
2023-04-13 |
4 |
B |
$0.29 |
$2,900 |
D/D |
10,000 |
106,901 |
2.66 |
9% |
|
| Yazji Salim |
Chief Medical Officer |
• – – |
2023-04-13 |
4 |
B |
$0.29 |
$2,850 |
D/D |
10,000 |
159,676 |
2.66 |
9% |
|
| Vincent Richard G |
Chief Financial Officer |
• – – |
2023-04-13 |
4 |
B |
$0.30 |
$8,961 |
D/D |
30,000 |
156,859 |
2.74 |
9% |
|
189 Records found
|
|
Page 1 of 8 |
|
|
